

Global Kinetics Corporation to Present Data on its Parkinson’s KinetiGraph (PKG) at the 21st International Congress of Parkinson’s Disease and Movement Disorders

Melbourne, Australia and San Francisco – May 23, 2017 – Global Kinetics Corporation (GKC), a leader in digital health technology for people with Parkinson’s disease, today announced that four abstracts have been accepted to the 21st International Congress of Parkinson’s Disease and Movement Disorders, occurring June 4-8 in Vancouver, British Columbia. The studies presented involve the company’s proprietary Parkinson’s KinetiGraph™ (PKG™) technology – called the Personal KinetiGraph™ in the US.

Abstract Title: “Using an Objective Measure of Movement to Quantify Night Time Sleep”
Presenting Author: Professor Malcolm Horne

Abstract Title: “Objective Data in Parkinson’s Disease: A description of over 10,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG)”
Presenting Author: Mr. Peter Lynch

Abstract Title: “An Evaluation of the Parkinson’s KinetiGraph (PKG) as a Tool to Support Deep Brain Stimulation Eligibility Assessment in Patients with Parkinson’s Disease”
Presenting Author: Professor Malcolm Horne

Abstract Title: “Objective Measurement in Clinical Care of Patients with Parkinson’s disease: an RCT using the PKG.”
Presenting Author: Professor Malcolm Horne

In addition to the four studies submitted by GKC, seven additional abstracts from outside clinics and research institutions centering on the utility of the PKG in routine clinical care in the US, UK and Europe will also be presented.

About Global Kinetics Corporation

Global Kinetics is a commercial-stage digital health company revolutionizing the management of Parkinson’s disease by providing the first continuous and objective measurement of patients’ symptoms in everyday environments. The company’s Parkinson’s KinetiGraph™ (PKG™) – called the Personal KinetiGraph™ in the US - is a patient-friendly, algorithm-based system that records body movements and other symptoms over the course of many days and creates data-driven reports that empower more personalized treatment and management decisions—with the goal of leading to a higher quality of life for patients. Global Kinetics continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure the efficacy of new and advanced therapies for the world’s most widespread movement disorder.

For more information, visit: www.globalkineticscorporation.com

US Media Contact

Carolyn Hawley

Canale Communications

619-849-5382

Carolyn@canalecomm.com